People with certain blood cancers or blood disorders may be candidates for a blood stem cell transplant. Other patients may qualify for a specific approved cell product or a clinical trial. Eligibility depends on the exact treatment, diagnosis, health risks, and ability to complete follow-up—not simply on wanting stem cell therapy. For transplantation, established uses include leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, aplastic anemia, and sickle cell disease, although a diagnosis alone does not establish suitability. Stem cell transplant
A private clinic offering to treat you is a different matter from evidence that its treatment is appropriate. Ask two separate questions: “Can I safely receive this procedure?” and “What evidence shows it could help someone with my condition?” This guide helps you prepare those questions; it cannot provide individual medical clearance.

Which Treatment Are You Considering?
Start with the product or procedure name, the cell type and source, how the cells are processed, and how they will be given. A blood-forming stem cell transplant is not interchangeable with a mesenchymal stromal cell (MSC) infusion. Even the distinction between autologous and allogeneic stem cells—your own cells versus donor cells—does not tell you whether a proposed use is supported.
Get the intended diagnosis, dose, route, treatment schedule, and regulatory pathway in writing. A study of one cell preparation or delivery route does not automatically support a different injection sold under the same broad “stem cell” label.
Who May Qualify for a Transplant?
Blood stem cell transplantation restores blood-forming cells after high-dose chemotherapy or radiation. Besides the conditions listed above, NCI describes uses in selected solid tumors, including neuroblastoma, Ewing sarcoma, recurrent brain tumors in children, germ cell tumors, and testicular cancer. Other cancer uses are being studied in clinical trials. Stem cell transplant
NCI identifies eight considerations for cancer-related transplantation: cancer type, how advanced it is, whether your own cells can be used, availability of matching donor cells, other treatments likely to work, tolerance of high-dose chemotherapy, other serious health problems, and previous treatment. These are factors to weigh, not eight universal pass-or-fail tests for every cell therapy. Stem cell transplant
If donor cells are needed, the team checks human leukocyte antigen (HLA) markers to assess matching. Using your own cells avoids donor matching, but in cancer treatment there is a risk that cancer cells could be collected with them. The choice depends on the disease and treatment plan. Stem cell transplant
Risks include infection, bleeding, infertility, and organ damage. Donor transplantation can also cause graft-versus-host disease, in which donor immune cells attack the recipient’s tissues. Recovery and access to specialist follow-up are part of suitability: NCI describes returning home around 100 days after donor-cell transplantation if there are no problems, with continued medical monitoring afterward. That is not a guaranteed recovery deadline. Stem cell transplant
Who Qualifies for an Approved Product?
Approval applies to a named product and a defined use, not to stem cells as a category. For example, on December 18, 2024, the U.S. FDA approved Ryoncil (remestemcel-L-rknd), a donor bone marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. This does not authorize MSC treatment for unrelated conditions or general rejuvenation. Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric
Ask the treating physician to match your diagnosis, age, previous treatment, and contraindications to the current prescribing information. FDA’s licensed-product list links to individual product records; appearing on that list does not mean a product is approved for every advertised use. U.S. approval also does not establish authorization in Japan or another country. Approved cellular and gene therapy products
Be careful with older summaries. FDA’s consumer alert, marked current as of April 9, 2024, predates the Ryoncil approval. Its “only cord-blood” wording should not be used as a current, exhaustive approval summary. The alert remains useful for understanding misleading marketing, but an individual offer needs checking against up-to-date product records. Consumer alert regenerative medicine products including stem cells and exosomes
Could You Join a Clinical Trial?
A trial has its own inclusion and exclusion criteria. NCI’s cancer-trial search guide gives examples: cancer type and stage, previous treatments, tumor genetic changes, age group, medical history, and current health. Meeting preliminary criteria means you may be considered; the study team must confirm eligibility. These examples come from cancer trials, not a universal checklist for all regenerative medicine studies. Steps
Ask for the study identifier, protocol, consent information, treatment alternatives, costs, and safety-monitoring arrangements. A registry entry confirms that information was registered; it does not establish that the intervention works. Likewise, PubMed indexing is not a quality rating. To assess results, check the human population, cell type, delivery route, study phase, participant numbers, comparison group, measured outcomes, follow-up, and adverse events.
What Might Delay or Rule Out Treatment?
There is no single exclusion list for every stem cell procedure. For transplantation, serious health problems, previous treatment, and ability to tolerate high-dose therapy affect the risk–benefit decision. For a trial, the protocol controls entry; for a licensed product, its prescribing information matters. Stem cell transplant Steps
Tell the clinician about current infection or fever, pregnancy or breastfeeding, organ disease, bleeding problems, cancer history, allergies, and all medicines. Ask which findings require treatment first, further testing, or a different option. Do not stop blood thinners, immune-suppressing drugs, or other prescribed medicines on your own to meet a clinic’s requirements.
There is no one age cutoff that applies to all these treatments. A product may have a specific age indication, as Ryoncil does, while a trial may set a different age range. “Too old” or “young enough” is not a complete eligibility assessment. Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric Steps
What Changes if Treatment Is in Japan?
Japan has a legal framework governing the provision of regenerative medicine, including procedures required before provision and rules for manufacturing certain cell preparations. A provision-plan filing under that framework is not the same thing as marketing approval for a product, nor is it proof that the proposed treatment will benefit you. Saisei_iryou
Ask the provider to identify the applicable legal route, exact product or plan, responsible medical institution, and current official record. Then ask separately for the human evidence supporting your diagnosis. The site’s Japan registration and compliance guide organizes the documents to request; use official records, rather than the website itself, to verify status.
What Should You Bring to a Consultation?
Prepare existing records rather than ordering tests yourself. The following checklist turns the diagnosis, treatment-history, and health factors described by NCI into questions for your clinician. It is preparation, not a medical clearance form. Stem cell transplant Steps
| Bring or clarify | Question to resolve |
|---|---|
| Diagnosis, subtype, stage, pathology, and relevant scans | Does my condition match the proposed treatment’s evidence and intended use? |
| Previous treatments, dates, responses, and side effects | Do earlier treatments affect my options or timing? |
| Available laboratory results and specialist reports | What additional checks are needed to assess risk? |
| Medicines, supplements, allergies, and current health concerns | Could anything interact with the procedure or require review? |
| The clinic’s written product or procedure details | Which approval, clinical protocol, or legal pathway applies? |
| Travel, caregiver, and follow-up arrangements | Who will manage complications after I leave? |
For international visits, the treatment-process guide for Japan covers record preparation and appointment coordination. Those support steps are separate from a physician’s decision about treatment.
Two Situations to Prepare For
If you are seeking a transplant opinion for leukemia, ask how your disease status, previous treatment, donor options, and fitness affect the recommendation. Bring the records needed to answer those questions, and ask which missing results could change the decision. Stem cell transplant
If a clinic offers an MSC infusion for knee pain, ask for evidence on that exact preparation, route, and condition. An approval for pediatric graft-versus-host disease does not answer that question. A useful written response should explain the proposed benefit, uncertainty, alternatives, and risks—not just say that you “qualify.” Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric
How Can You Check a Clinic’s Answer?
Before paying or booking travel, ask for the clinical recommendation, evidence, full fees, cancellation terms, and follow-up responsibilities in writing. For Japan, questions about institutional records, costs, and aftercare can be organized using the provider-selection checklist. Verify the answers independently when the intervention is costly, experimental, or would delay standard care.
A quick reply is not automatically unsafe, and a slow reply is not proof of care. What matters is whether the recommendation addresses your records, the exact intervention, alternatives, and unresolved risks.
Promises of a cure, pressure to pay before a medical assessment, and testimonials presented as substitutes for clinical evidence are reasons to pause. FDA warns that misleading regenerative-medicine marketing can expose patients to products whose safety and effectiveness have not been demonstrated. Consumer alert regenerative medicine products including stem cells and exosomes
Need help preparing questions for a clinic appointment in Japan? Contact the independent patient support team about appointment coordination. Medical eligibility is assessed by the treating physician.
The Bottom Line
You may be a candidate when a specific treatment fits your condition and its likely benefits justify its risks. Transplant suitability, approved-product eligibility, trial entry, and a private clinic’s willingness to treat are not interchangeable. Get a diagnosis-specific recommendation from a qualified treating physician before committing to treatment.
Sources
- National Cancer Institute. Stem Cell Transplants in Cancer Treatment.
- U.S. Food and Drug Administration. Ryoncil approval for pediatric steroid-refractory acute graft-versus-host disease. December 18, 2024.
- U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products.
- U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Content dated April 9, 2024; not a current exhaustive approval list.
- National Cancer Institute. Steps to Find a Clinical Trial.
- Japan Ministry of Health, Labour and Welfare. Regenerative, Cellular, and Gene Therapy Information.




